Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on CNS, inflammatory and cardiometabolic diseases, has announced a proposed public offering of common stock and warrants. The offering will include shares of common stock (or equivalents) and warrants to purchase common stock, with A.G.P./Alliance Global Partners serving as the sole placement agent.
The proceeds will be used to fund research and development activities and for working capital purposes. The securities will be offered through an effective shelf registration statement on Form S-3. The completion of the offering is subject to market conditions, with no guaranteed size or terms.
Reviva Pharmaceuticals (NASDAQ: RVPH), una società farmaceutica in fase avanzata focalizzata su disturbi CNS, infiammatori e cardiometabolici, ha annunciato una proposta di offerta pubblica di azioni ordinarie e warrant. L'offerta includerà azioni ordinarie (o equivalenti) e warrant per l'acquisto di azioni ordinarie, con A.G.P./Alliance Global Partners che agirà come unico agente di collocamento.
I proventi saranno utilizzati per finanziare attività di ricerca e sviluppo e per esigenze di capitale circolante. I titoli saranno offerti tramite una dichiarazione di registrazione shelf efficace in Form S-3. Il completamento dell'offerta è soggetto alle condizioni di mercato, senza garanzia di dimensioni o termini.
Reviva Pharmaceuticals (NASDAQ: RVPH), una empresa farmacéutica en etapa avanzada centrada en trastornos del CNS, inflamatorios y cardiometabólicos, ha anunciado una propuesta de oferta pública de acciones ordinarias y warrants. La oferta incluirá acciones ordinarias (o sus equivalentes) y warrants para comprar acciones ordinarias, con A.G.P./Alliance Global Partners como único agente de colocación.
Los fondos se utilizarán para financiar actividades de investigación y desarrollo y para fines de capital de trabajo. Los valores se ofrecerán a través de una declaración de registro tipo shelf efectiva en Formulario S-3. La culminación de la oferta está sujeta a condiciones de mercado, sin tamaño ni términos garantizados.
Reviva Pharmaceuticals (나스닥: RVPH), CNS, 염증 및 심대사 질환에 중점을 둔 후기 단계 제약 회사는 일반주와 워런트의 공개 제안을 발표했습니다. 제공에는 일반주(또는 동등물)와 일반주를 매입할 수 있는 워런트가 포함되며, A.G.P./Alliance Global Partners가 단독 배정 대리인으로 활동합니다.
모집 자금은 연구 개발 활동 자금 조달과 운전자본 목적에 사용될 예정입니다. 증권은 Form S-3의 효과적인 선반 등록 문서를 통해 제안됩니다. 제안의 완료는 시장 상황에 좌우되며, 규모나 조건이 보장되지 않습니다.
Reviva Pharmaceuticals (NASDAQ: RVPH), une société pharmaceutique en phase avancée axée sur les troubles du SNC, inflammatoires et cardiométaboliques, a annoncé une offre publique proposée d'actions ordinaires et de bons de souscription. L'offre comprendra des actions ordinaires (ou leurs équivalents) et des bons de souscription pour l'achat d'actions ordinaires, A.G.P./Alliance Global Partners servant d'unique agent de placement.
Les fonds seront utilisés pour financer des activités de recherche et développement et pour des fins de fonds de roulement. Les titres seront offerts par le biais d'une déclaration d'enregistrement sur étagère effective au formulaire S-3. L'achèvement de l'offre est soumis aux conditions du marché, sans garantie de taille ou de termes.
Reviva Pharmaceuticals (NASDAQ: RVPH), ein im Spätstadium tätiges Pharmaunternehmen mit Fokus auf CNS-, Entzündungs- und cardiometabolische Erkrankungen, hat eine vorgeschlagene öffentliche Angebot von Stammaktien und Warrants angekündigt. Das Angebot umfasst Stammaktien (oder äquivalente Werte) und Warrants zum Kauf von Stammaktien, wobei A.G.P./Alliance Global Partners als alleiniger Platzierungsvertreter fungieren wird.
Die Erlöse sollen für Forschung und Entwicklung und für Betriebsmittel verwendet werden. Die Wertpapiere werden über eine effektive Shelf-Registrierungserklärung auf dem Formular S-3 angeboten. Der Abschluss des Angebots hängt von den Marktbedingungen ab, es gibt keine Garantie für Größe oder Konditionen.
Reviva Pharmaceuticals (النُسخة: RVPH)، شركة أدوية في مرحلة متأخرة تركز على أمراض الجهاز العصبي المركزي والالتهابات والأمراض القلبية-الاستقلابية، أعلنت عن عرض عام مقترح لأسهم عادية ومرابحات. سيشمل العرض أسهماً عادية (أو ما يعادلها) ومرابحات لشراء أسهم عادية، مع A.G.P./Alliance Global Partners كوكيل طرح وحيد.
سيُستخدم العائدات لــ تمويل أنشطة البحث والتطوير ولأغراض رأس المال العامل. ستتم عروض الأوراق المالية من خلال بيان تسجيل على رف shelf فعّال وفق النموذج S-3. إتمام العرض مشروط بالظروف السوقية، ولا توجد ضمانات لحجم أو شروط.
Reviva Pharmaceuticals (纳斯达克：RVPH)，一家专注于中枢神经系统、炎症和心代谢疾病的晚期药企，宣布拟公开发行普通股及认股权证。此次发行将包括普通股（或等值物）及认股权证以购买普通股，A.G.P./Alliance Global Partners将担任唯一承销商。
募集资金将用于资助研究与开发活动及营运资金用途。证券将通过有效的Shelf注册声明（S-3表格）进行发行。发行的完成取决于市场状况，未设定保障的规模或条款。
- Potential to strengthen company's cash position for R&D activities
- Funds will support working capital and general corporate purposes
- Potential dilution for existing shareholders
- Uncertainty regarding the final size and terms of the offering
Insights
Reviva's proposed public offering signals potential dilution for existing shareholders while raising capital for R&D and operations.
Reviva Pharmaceuticals (NASDAQ: RVPH) has announced a proposed public offering of common stock and warrants, signaling a significant capital-raising effort that will likely dilute existing shareholders. The company, which focuses on developing therapies for CNS, inflammatory, and cardiometabolic diseases, hasn't disclosed the size or pricing of the offering—key details that will determine the extent of dilution and capital infusion.
The offering includes both common stock (or equivalents) and warrants, suggesting management is pursuing a more complex financing structure than a straightforward equity raise. This approach typically provides investors with additional upside potential through the warrants while potentially making the offering more attractive in challenging market conditions.
Reviva's disclosed use of proceeds focuses on funding research and development activities and general working capital, indicating the company needs additional financial runway to advance its late-stage pharmaceutical pipeline. For development-stage biotech companies like Reviva, periodic capital raises are often necessary to fund clinical trials and regulatory submissions, which require substantial capital before generating revenue.
The fact that A.G.P./Alliance Global Partners is acting as the sole placement agent rather than a syndicate of banks suggests this may be a relatively smaller offering. The company has an active shelf registration statement from February 2024, which streamlines this capital-raising process. Importantly, the "subject to market conditions" language indicates that pricing, timing, and even completion of the offering remain uncertain and will depend on investor reception.
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Reviva. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
The Company currently intends to use the net proceeds from the offering to fund research and development activities and for working capital and other general corporate purposes.
The securities will be offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-276848), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 2, 2024, and declared effective by the SEC on February 13, 2024. A preliminary prospectus supplement will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying base prospectus, when available, may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering and uncertainties related to the size, timing, completion, and use of proceeds from the proposed offering. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s prospectus supplement to be filed with the SEC, and the documents incorporated by reference therein, including the Company’s Form 10-K for the year ended December 31, 2024 and Forms 10-Q for the quarters ended March 31, 2025 and June 30, 2025.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
REVIVA CONTACTS:
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
What is the purpose of Reviva Pharmaceuticals' (RVPH) new public offering?
Who is the placement agent for RVPH's public offering?
What securities are being offered in RVPH's public offering?
When was RVPH's shelf registration statement declared effective?
What therapeutic areas does Reviva Pharmaceuticals focus on?
